Last reviewed · How we verify

NCT02755623: TMSCCS

Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations

Status unknown NA Last updated 15 February 2024
What this trial tests

NA trial testing Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia in 45 participants. Status unknown.

Timeline
14 October 2015
Primary endpoint
8 September 2025
8 October 2025

Quick facts

Lead sponsorCentre hospitalier de Ville-Evrard, France
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment45
Start date14 October 2015
Primary completion8 September 2025
Estimated completion8 October 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre hospitalier de Ville-Evrard, France

Who can join

Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The potential of non-invasive Transcranial Magnetic Stimulation (TMS) as a therapeutic tool for improving schizophrenic symptoms, in particular resistant hallucinations, has been increasingly studied over the past decades. Several studies have demonstrated that low-frequency patterns of repetitive TMS (rTMS) applied over the left Temporoparietal Junction (TPJ), which are known to decrease local activity, significantly reduced auditory verbal hallucinations in schizophrenic patients. In spite of highly promising results, a high level of inter-individual variability in the responses to non-invasive brain stimulation treatments, and the fact that rTMS may prove ineffective in some patients, keep spurring controversy about the efficacy of these approaches (as currently performed), as well as about how to increase its efficacy and consistency. Accordingly, the objectives of this project are to better understand the impact of rTMS on the brains of patients with resistant auditory hallucinations, and to use this information not only to better understand this condition but to develop more efficient and consistent therapies. Thus, in this study, the investigators focus more specifically on resistant auditory hallucinations in schizophrenia, which is a common symptom in schizophrenic patients, and can be treated by rTMS. The investigators hypothesize that there is a baseline difference in anatomical and/or functional connectivity between responder and non-responder patients who are treated with rTMS. Therefore, our project will aim to determine some anatomical and functional connectivity markers of response to rTMS treatment in patients with schizophrenia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Structural and functional brain biomarkers of clinical response to rTMS of medication-resistant auditory hallucinations in schizophrenia patients: study protocol for a randomized sham-controlled double-blind clinical trial.
    Thomas F, Bouaziz N, Gallea C, Schenin-King Andrianisaina P, et al · · 2019 · cited 5× · PMID 31014369 · DOI 10.1186/s13063-019-3311-x

Verify or expand the search:

Other trials of Repetitive Transcranial Magnetic Stimulation (rTMS)

Trials testing the same drug.

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

Other Centre hospitalier de Ville-Evrard, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02755623.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing